Alaunos Therapeutics (NASDAQ: TCRT), a clinical-stage T-cell receptor (TCR) therapy company, is in retreat mode. Specifically, the biotech's share price fell by as much as 10.1% during Monday's trading session.

Shares have recovered to some degree since, but this small-cap biotech stock was still lower by a hefty 8.58% as of 3:48 p.m. ET. 

What's weighing on Alaunos' shares today? Alaunos' stock roared higher last week by a whopping 64.4%, thanks to an upcoming medical conference presentation titled "Objective clinical response by KRAS mutation-specific TCR-T cell therapy in previously treated advanced Non-small cell lung cancer."

Continue reading

Source Fool.com